FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2023969085> ?p ?o ?g. }

• W2023969085 endingPage "547" @default.
• W2023969085 startingPage "544" @default.
• W2023969085 abstract "The number of patients on antithrombotic treatment due to atrial fibrillation and venous thromboembolism is increasing fast due to an aging population. A growing proportion will be treated with novel oral anticoagulants, the first in clinical use was the direct oral thrombin inhibitor dabigatran (Pradaxa®). A small percentage of the patients on dabigatran will experience serious bleeding or be in need of urgent surgery. The aim of this study was to test the effects of different hemostatic agents in potentially reversing the anticoagulant effects in vitro in blood or platelet-rich plasma (PRP) spiked with dabigatran. Whole blood or PRP was spiked with the active substance dabigatran, 200 μg/L. We measured clotting time being induced by 1.4 pmol/L tissue factor using the instrument ReoRox2™ and initial clot growth velocity from a tissue factor covered surface using the instrument Thrombodynamics Analyzer T-2™. Dabigatran prolonged clotting time 5-fold but reduced clot growth velocity only slightly. The reversing effects of prothrombin complex concentrates (PCC), activated PCC (APCC) and recombinant activated factor VII (rFVIIa) were then tested. APCC (1.8 U/mL) reduced the prolonged clotting time by 1/3, rFVIIa (2 μg/L) only slightly (n = 10-20). The reduction was not significant using Mann-Whitney test but significant using t-test with Bonferronis' correction for multiple comparisons, whereas PCC (0.56 U/mL) had no effect on clotting time. APCC doubled initial clot growth velocity, although even more in the absence of dabigatran. In conclusion, APCC and rFVIIa, but not PCC, seem to reverse, at least partially, some effects of dabigatran on coagulation parameters. Systematic evaluation of case reports, registries and, ultimately, randomized clinical trials are needed to elucidate potential benefit for patients." @default.
• W2023969085 created "2016-06-24" @default.
• W2023969085 creator A5004228898 @default.
• W2023969085 creator A5020075671 @default.
• W2023969085 creator A5032727757 @default.
• W2023969085 creator A5060285944 @default.
• W2023969085 creator A5072494726 @default.
• W2023969085 date "2015-03-01" @default.
• W2023969085 modified "2023-09-26" @default.
• W2023969085 title "More efficient reversal of dabigatran inhibition of coagulation by activated prothrombin complex concentrate or recombinant factor VIIa than by four-factor prothrombin complex concentrate" @default.
• W2023969085 cites W1530521222 @default.
• W2023969085 cites W1575823155 @default.
• W2023969085 cites W1971941179 @default.
• W2023969085 cites W1975897275 @default.
• W2023969085 cites W1981700108 @default.
• W2023969085 cites W1990272483 @default.
• W2023969085 cites W1993627870 @default.
• W2023969085 cites W2000922667 @default.
• W2023969085 cites W2011090717 @default.
• W2023969085 cites W2019452561 @default.
• W2023969085 cites W2022451762 @default.
• W2023969085 cites W2031458609 @default.
• W2023969085 cites W2032709663 @default.
• W2023969085 cites W2043820340 @default.
• W2023969085 cites W2046186673 @default.
• W2023969085 cites W2046188252 @default.
• W2023969085 cites W2081326224 @default.
• W2023969085 cites W2084827367 @default.
• W2023969085 cites W2101863341 @default.
• W2023969085 cites W2134816037 @default.
• W2023969085 cites W2138508804 @default.
• W2023969085 cites W2153134011 @default.
• W2023969085 cites W2159578495 @default.
• W2023969085 cites W2169585147 @default.
• W2023969085 cites W2334285353 @default.
• W2023969085 cites W2481569543 @default.
• W2023969085 doi "https://doi.org/10.1016/j.thromres.2014.12.019" @default.
• W2023969085 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25596769" @default.
• W2023969085 hasPublicationYear "2015" @default.
• W2023969085 type Work @default.
• W2023969085 sameAs 2023969085 @default.
• W2023969085 citedByCount "29" @default.
• W2023969085 countsByYear W20239690852015 @default.
• W2023969085 countsByYear W20239690852016 @default.
• W2023969085 countsByYear W20239690852017 @default.
• W2023969085 countsByYear W20239690852018 @default.
• W2023969085 countsByYear W20239690852019 @default.
• W2023969085 countsByYear W20239690852020 @default.
• W2023969085 crossrefType "journal-article" @default.
• W2023969085 hasAuthorship W2023969085A5004228898 @default.
• W2023969085 hasAuthorship W2023969085A5020075671 @default.
• W2023969085 hasAuthorship W2023969085A5032727757 @default.
• W2023969085 hasAuthorship W2023969085A5060285944 @default.
• W2023969085 hasAuthorship W2023969085A5072494726 @default.
• W2023969085 hasBestOaLocation W20239690852 @default.
• W2023969085 hasConcept C126322002 @default.
• W2023969085 hasConcept C186738567 @default.
• W2023969085 hasConcept C2776301958 @default.
• W2023969085 hasConcept C2776710957 @default.
• W2023969085 hasConcept C2777091921 @default.
• W2023969085 hasConcept C2777987278 @default.
• W2023969085 hasConcept C2778205648 @default.
• W2023969085 hasConcept C2778382381 @default.
• W2023969085 hasConcept C2778661090 @default.
• W2023969085 hasConcept C2778810321 @default.
• W2023969085 hasConcept C2778961111 @default.
• W2023969085 hasConcept C2779161974 @default.
• W2023969085 hasConcept C42219234 @default.
• W2023969085 hasConcept C71924100 @default.
• W2023969085 hasConcept C77171857 @default.
• W2023969085 hasConcept C98274493 @default.
• W2023969085 hasConceptScore W2023969085C126322002 @default.
• W2023969085 hasConceptScore W2023969085C186738567 @default.
• W2023969085 hasConceptScore W2023969085C2776301958 @default.
• W2023969085 hasConceptScore W2023969085C2776710957 @default.
• W2023969085 hasConceptScore W2023969085C2777091921 @default.
• W2023969085 hasConceptScore W2023969085C2777987278 @default.
• W2023969085 hasConceptScore W2023969085C2778205648 @default.
• W2023969085 hasConceptScore W2023969085C2778382381 @default.
• W2023969085 hasConceptScore W2023969085C2778661090 @default.
• W2023969085 hasConceptScore W2023969085C2778810321 @default.
• W2023969085 hasConceptScore W2023969085C2778961111 @default.
• W2023969085 hasConceptScore W2023969085C2779161974 @default.
• W2023969085 hasConceptScore W2023969085C42219234 @default.
• W2023969085 hasConceptScore W2023969085C71924100 @default.
• W2023969085 hasConceptScore W2023969085C77171857 @default.
• W2023969085 hasConceptScore W2023969085C98274493 @default.
• W2023969085 hasIssue "3" @default.
• W2023969085 hasLocation W20239690851 @default.
• W2023969085 hasLocation W20239690852 @default.
• W2023969085 hasLocation W20239690853 @default.
• W2023969085 hasOpenAccess W2023969085 @default.
• W2023969085 hasPrimaryLocation W20239690851 @default.
• W2023969085 hasRelatedWork W1486815316 @default.
• W2023969085 hasRelatedWork W1996911008 @default.
• W2023969085 hasRelatedWork W2021321073 @default.
• W2023969085 hasRelatedWork W2023969085 @default.
• W2023969085 hasRelatedWork W2041195426 @default.

• next